For Investors

Linshom is an early stage, privately held start-up company with a mission to eliminate the morbidity‭, ‬mortality‭, ‬and expense due to unrecognized respiratory decline in healthcare.‬

Recent FDA clearance (Jan, 2020),  Linshom is currently raising a series A round of funding that the company will use to refine the existing sensor and integrate into a multi-parameter monitor. In parallel Linshom will continue developing the evidence needed for rapid clinical adoption.

Investment History

• $3.6M Non-dilutive funds raised (NIH & US Air Force grants)
• $1.6M Convertible Note complete (fully converted to Series A Shares)
• $3.0M Series A Preferred round currently open for investment by "qualified investors"
  • Seeking $1.2M to close the Series A round
  • $1.8 M closed and led by:

Linshom overview on GUST

Linshom overview on Dealum

Press Releases